BioSpace News Archive

Transcenta Holding Limited announces that TST003, its first-in-class, high affinity humanized monoclonal antibody targeting Gremlin1, has received IND clearance from U.S. Food and Drug Administration.

Pharnext SA announces the publication of symptom burden findings of Charcot-Marie-Tooth Disease Type1A from the ‘Real-World’ Digital Lifestyle Study, CMT&Me, in the Journal of Clinical Neuromuscular Disease.

Samsung Bioepis Co., Ltd. announced that it has attained two ISO certifications: ISO 140001 and ISO 50001 from Lloyd’s Register Quality Assurance, reflecting the company’s ongoing practices and commitment to becoming a sustainable company.

Revive Therapeutics Ltd. announced that it has filed an amended protocol to the U.S. Food & Drug Administration for the Company’s Phase 3 clinical trial to evaluate the safety and efficacy of Bucillamine, an oral drug with anti-inflammatory and antiviral properties, in patients with mild to moderate COVID-19.

About 66% of U.S. residences burn methane gas, wood, propane, heating oil or other fuel for heating, drying clothes and cooking food.

Ocugen, Inc. announced the publication “A comprehensive review of BBV152 vaccine development, effectiveness, safety, challenges, and prospects” appeared in Frontiers in Immunology.

Kineta, Inc., a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology, announced that Thierry Guillaudeux, Ph.D., Kineta’s Chief Scientific Officer, has been invited to present at the 2nd Annual VISTA Symposium.

Enzolytics, Inc. announces the successful conclusion, in a Delaware Federal litigation, 21-CV-01163-RGA, brought by Peter Mergenthaler against Enzolytics. Enzolytics’ Motion to Dismiss was granted by the Federal District Court terminating the case.

ASLAN Pharmaceuticals (“ASLAN”, Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that it plans to initiate a new clinical trial of eblasakimab for the treatment of moderate-to-severe atopic dermatitis (AD) in adult patients who have previously been treated with dupilumab.

Notice of Allowance of Patent Application for the Use of B-Raf Inhibitors for Treating Cutaneous Reactions Caused by Treatment with a MEK Inhibitor Further Expands Lutris’ Comprehensive Intellectual Property Portfolio Until 2038.